I guess this is better than the alternative:
Funding Agreement with AXA Health UK
13 December 2022
• DOC secures £10 million loan from AXA
• Variation of AXA Agreements
• Full settlement of historic service level credits arising from platform issues
Doctor Care Anywhere Group PLC (ASX:DOC, “Doctor Care Anywhere” or “the Company”) today announces that its subsidiary, Doctor Care Anywhere Limited (“DCA Limited”), has entered into a four-year secured and guaranteed loan agreement with AXA PPP Healthcare Group Limited ("AXA") to borrow up to £10,000,000 in 3 tranches ("Loan"). The Loan will be used by the Company for general working capital purposes in accordance with the terms of the Loan. An overview of the key terms of the Loan is set out in the Attachment.
Chairman Richard Dammery said: “AXA is Doctor Care Anywhere’s major partner and its primary source of revenue, and has provided DCA with strong support over time. Today’s announcement is further evidence of its belief in the Doctor Care Anywhere service as an important benefit to its members. The agreements announced today obviously increase DCA’s dependence on AXA, and enhance AXA’s rights in relation to the Company, but they also ensure that the Company can continue to develop innovative healthcare pathways into 2023 and beyond”.
Chief Executive of AXA Health UK, Tracy Garrad said: “Our partnership with Doctor Care Anywhere provides a much valued offering to our members, so providing financial support to DCA was imperative to ensure continuity of service to AXA's clients”.
Amendment to AXA Joint Venture Agreement
Under the terms of their Joint Venture Agreement (“JVA”), AXA and the Company undertook to each other, and agreed to procure that their affiliates will not, for so long as they are a party to the JVA, be concerned with, engaged or interested in any business that is in competition with the joint venture in the UK or Republic of Ireland. Doctor Care Anywhere and AXA have now agreed to vary certain terms of their agreements to permit AXA to enter into discussions with alternative service providers for the purposes of AXA’s own business continuity planning. AXA shall not be entitled to appoint an alternative service provider to Doctor Care Anywhere, or make a similar proposition available to its customers, unless the relevant restrictive covenants otherwise cease to apply to AXA in accordance with the existing terms of the JVA and related agreements. This includes as a result of various specified events of default.
Settlement of historic service level credits with AXA arising from platform issues
In the Company’s Market Update of 23 August 2022, DOC indicated that AXA has contractual rights to receive service credits when the group's performance fails to meet agreed service levels. At that time, AXA had agreed not to enforce these service credits immediately, with the Company to direct the funds towards platform stability initiatives and other IT integration projects, to the mutual benefit of AXA and the Company. DOC and AXA have now agreed that £750,000 will be payable by DOC in full settlement of all known historic service level credits due to date under the MSA. Payment by the Company will be deferred to the end of the Loan term.
An update on the Company’s operating performance will be provided at the time of its preliminary full-year results announcement, anticipated to be at the end of February 2023.
This announcement has been authorised for release by the Board of Directors of the Company.
Amount: Commencement Date: Term:
Maturity Date: Purpose:
ATTACHMENT: OVERVIEW OF KEY TERMS OF AXA LOAN
AXA PPP Healthcare Group Limited
Doctor Care Anywhere Limited (“DCA Limited”), a wholly
owned subsidiary of Doctor Care Anywhere Group PLC ("DOC") £10 million
12 December 2022
30 November 2026
Working capital requirements of DOC and its subsidiaries (the "Group").
Accruing quarterly, but all interest shall be paid in full on the Maturity Date. If the borrower obtains debt finance from a third party at a yield (i.e. fees, commission, interest rate and interest rate floor) that is higher than the rate payable to AXA, the interest rate on the Loan shall rise to match the yield paid to such third party.
Assuming Tranches 1, 2 and 3 are drawn down at the earliest opportunity, the total Interest payable in the form of a one-off payment in Dec 2026 is c.£1.1m.
The Loan is available in three tranches. Tranche 1 of £5m is available for 3 months from the initial entry into the loan, Tranche 2 of £2.5m is available for 3 months from 1 March 2023 and Tranche 3 of £2.5m is available for 3 months from 1 June 2023, in each case provided certain conditions precedent are met.
Tranche 1 can be drawn upon the provision of certain specified documents and information to AXA.
Tranche 2 can be drawn upon provision to AXA of IT Development Plans, in a form acceptable to AXA (acting reasonably).
Tranche 3 likewise can be drawn upon provision of evidence to AXA that all milestones set out in the IT Development Plans have been delivered.
In addition, and as is standard, Tranche 2 and Tranche 3 can be drawn if at the respective time of drawdown, no event of default or potential event of default is continuing.
Guarantee and Security:
The Loan is guaranteed by DOC and its subsidiaries DCA Limited, DCA Innovation Limited and Doctor at Hand Diagnostics Limited (together, the "Subsidiaries"). To secure the Loan, the Subsidiaries will grant AXA a debenture creating fixed and floating charges over all their assets and undertaking and DOC will grant AXA a pledge over all its shares in the Subsidiaries.
Principal amount is repayable in full on a straight line basis by repaying 1/13th of the total aggregate principal outstanding from 30 November 2023 and thereafter (i.e. quarterly), with the last repayment due on 30 November 2026.
Interest will be capitalised to the Interest Reserve and will be repayable as a bullet repayment on the Maturity Date, along with £750k of agreed SLA credits.
Additional Repayment conditions:
Entire balance (principal and interest) will be immediately repayable upon any of the following:
(a) it becomes unlawful in any jurisdiction for the Lender to comply with its obligations under the loan agreement;
(b) change of control of any of DOC or the Subsidiaries; or
(c) sale of all or substantially all the assets of any of DOC or the Subsidiaries.
• DOC shall provide AXA with:
o its annual audited consolidated accounts and the Subsidiaries audited accounts (within 180 days of its financial year end);
o its6monthlyunauditedconsolidatedaccounts (within 30 days of the end of that 6 month period)
o itsconsolidatedmonthlyaccountsfortheGroup (within 15 days after the end of each month).;and
o 12 month look forward liquidity forecast delivered monthly (within 5 business days of the end of each month) to include summary of cash inflows/outflows and cash.
• AXA has the right to a business meeting with DOC monthly for the first 6 months, quarterly for the remainder of the term.
Standard general undertakings to restrict the ability of the Group to take certain actions without AXA's consent including: sell the business, dispose of assets, declare dividends (except where recipient is DOC or a Subsidiary, so DOC in particular cannot declare dividends), restriction on director drawings (except for drawings as agreed at signing) change the nature of the business, make acquisitions, incur additional debt, give guarantees, make loans, grant security to other parties (negative pledge), incur capex above £500k without AXA's consent (not to be unreasonably withheld or delayed), enter into transactions other than on arm’s length terms, authorisations and compliance with laws and restrictions on movements of cash. Certain permitted exceptions to be agreed between the parties and in particular:
DOC can issue ordinary shares to its shareholders for cash provided it does not lead to a change of control;
From 1 October 2023 the Group can incur additional indebtedness of up to 4x next 12 months forecast EBITDA (4x threshold increasing to 4.5x for the year ending 31 December 2025 and 5x for the year ending 31 December 2026); and
DOC shall be permitted to sell GP2U / Psych2U and other non- material assets.
Representations: Standard reps and warranties
Events of default:
Standard events of default including: non-payment (subject to a remedy period of 5 business days), cross-default, misrepresentation (subject to a remedy period of 10 business days), insolvency or insolvency proceedings, creditors’ process, breach of undertakings (subject to a remedy period of 10 business days), unlawfulness or invalidity, cessation of business, change of ownership, litigation, audit qualification, material adverse change and breach of liquidity covenant (being triggered where: (i) DCA Limited’s 12 month look forward liquidity position drops below £3 million; or (ii) DCA Limited 's monthly cash end balance is less than £3million– tested monthly by reference to 12 month look forward liquidity forecast and accounts). The forecast can be supported by planned draw down of debt under the loan agreement). Any
termination of the JVA, Master Services Agreement, Side Letter and other material agreements made between AXA and the Group, shall also constitute an Event of Default.
Publicity AXA and DOC to agree any announcements except where required by law or the rules of any financial market
Governing Law and English law. Courts of England and Wales Jurisdiction:
Founder and CEO who is a doctor with experience in business and consulting before starting DOC is “retiring” to no longer be part of the company.
I think they raised capital just a bit too late. Thus, when they became a baby thrown out with the bath water, it didn’t have the balance sheet to survive.
With an impending capital raise likely to be very dilutive and the founder now gone, I’m not sure how investors can win here. A bidding war and takeover does not seem that likely.
Doctor Care Anywhere Trading Halt.
A lot of negative chat on forums - will see what this Wednesday brings when the announcement is made to the market.
@Byrnesty i think you're probably correct on all factors, maybe i am Anchoring, maybe I'm to early (done that before) maybe i am just wrong, but I do believe this will eventually get over the line and become a company worth owning.
Certainly understand your frustration - I'm gonna hang on for now though.
Hope you get a better return from future Investments than you you got with this one.
@Summer12 I used to share your optimism on this company but as of today I am selling out.
I have flagged my previous concerns about the cash burn rate and the dwindling cash reserves.
For the last 6 months DOC have burned £9.07M and currently have £12.4M available. There must be a cap raise coming shortly.
The last cap raise (March 2022) was undertaken at a 17% discount to the VWAP (A$0.31) with a securityholder participation rate of 0.73%.
With the SP currently A$0.195 another cap raise will be brutal.
I figure that if I change my mind I can always buy back in during the next cap raise where the SP will be smashed.
Increased revenue, decreasing costs - still away from profitability but heading in the right direction at least.
DISC - Hold.
Nice to see the Doctor Care Anywhere CE on Auzbiz today.
Seems like he's on a bit of a whirl wind tour promoting the company and talking up the financials and growth, along with path to profitability. - quick Interview but i liked it,
However i always cringe when i hear Annette Beacher speak to anyone as she often seems to get the Panel guests name or company wrong.
Attached is a very detailed article on Doctor Care Anywhere - (Hope the link works)
The article discusses 10 points that indicate how this company can achieve great financial results for shareholders and become a disruptive game changer.
Doctor Care Anywhere Investor Presentation scheduled for 23rd February 2022 - Discussing financials for year end 2021.
I am very firm believer in this company and sector.
Disc - Hold IRL and SM.
Note that FY's align with calendar years for DOC.
Update 30 January 2022 (Full Year Results).
Revenue growth strong at 35.9% Q4 over Q3 and 115.7% 2021 over 2020. Guidance was for 100% growth.
Consultations increased 22.7% Q4 over Q3.
Note from the App 4C that only 3 quarters of cash available at the current cash burn rate ($5.3M per quarter). This may hinder any short term share price growth as there will likely be a cap raise in the near term. A cap raise at this price would be very dilutive.
Another headwind is the Australian Govt medicare rebate for telehealth services ends on 30 June 2022 (unless extended). At this time the Australian operations appear to generate only 10% of revenue, but still an issue to monitor.
Patient number growth is driven through 20% cost savings to insurance and hospital partners who refer patients to DOC.
Continued growth is reliant on growth of partners referrals.
While I like the growth I feel there are some warning bells ringing here.
Hold for now but on a very short leash.
Update 24 October 2021.
DOC 3rd QTR results are in line with previous guidance.
Management has re-confirmed full year revenue growth of 100% above FY20 (excluding acquisitions).
4th QTR revenue needs to grow by only 7% over 3rd QTR to achieve this guidance. CAGR of 139% over 3 years since 4th QTR 2018 would suggest full year guidance will be easily exceeded.
Currently valued at a relatively low revenue multiple of 5.1 (based on current SP of $0.715) which is comparatively low for a 3yr CAGR of 139%.
I see comparisons between on-line retail and telehealth as to how they are impacted by consumer trends during the re-opening phase. Results during the next two QTR’s will be telling.
Maintain current valuation of $0.82.
9 September 2021Announced today the purchase of Australian based telehealth provider GP2U Telehealth Pty Ltd for A$11M in cash and shares. Purchase based on 2.5x Gross revenue multiple. DOC (as of yesterday COB) trades on a FY21 forecast revenue multiple of 5.87. On the investor call this morning management confirmed that FY21 will achieve the forecast revenue growth of 100% above FY20 without including this acquisition. So projecting forward to December 2021 we get revenue of A$42.9M (organic growth) + A$4.4M (acquisition) = A$47.3M total revenue. Share count will increase from 327.18M to 337.74M due to the acquisition. Maintaining the existing multiple the fair share price today is $0.82.
Pleased to see DOC had a decent 15.3% gain today without any news and on fairly decent trading volumes for a shortened trading day.
I have a theory that the rampant spread of the omicron variant in the UK will provide a significant tailwind for DOC for at least the near term. Reported more than 500,000 cases in the previous 7 days with restrictions re-imposed in Europe.
DOC appeared to be oversold recently so I added to my existing RL holding with a short term trade in mind. I'll look to exit the 'extra holding' on the 4th qtr results in January which should reflect increased consultations and revenue.
This is not my usual investment strategy but it looked to be worth a try.
Merry Christmas to all.
DOC mistake in cashflow statement this morning. should be -5.1m pounds not - 51.1m !! not held
? Unaudited revenue totalled £11.6m in FY 2020, up 102% on FY 2019
? Unaudited revenue totalled £3.8m in 4Q 2020, up 151% on 4Q 2019
? Eligible Lives of 2.2m at end of 4Q 2020 up 186% on 4Q 2019
? Activated Lives at end 4Q 2020 up 199% on 4Q 2019
? Consultations for 4Q 2020 up 333% on 4Q 2019 ? Successful A$102m IPO on ASX on 4 December 2020
? Strong cash position of £38.4 million as at 31 December 2020
? New channel agreement with Allianz Partners embeds DOC into Allianz UK and European international private medical insurance policies from 1 January 2021 ? First international expansion completed with entry into Republic of Ireland
You can copy and paste below for their presentation
Disc: I Hold